BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26849680)

  • 1. Application of a Persistent Heparin Treatment Inhibits the Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes.
    Sento S; Sasabe E; Yamamoto T
    PLoS One; 2016; 11(2):e0148454. PubMed ID: 26849680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis.
    Sasabe E; Tomomura A; Liu H; Sento S; Kitamura N; Yamamoto T
    Cancer Sci; 2022 Feb; 113(2):609-621. PubMed ID: 34874595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.
    Lee JC; Chung LC; Chen YJ; Feng TH; Chen WT; Juang HH
    Cancer Lett; 2015 May; 360(2):310-8. PubMed ID: 25721086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma.
    Xiao M; Zhang J; Chen W; Chen W
    J Exp Clin Cancer Res; 2018 Jul; 37(1):143. PubMed ID: 29986759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo.
    Chung LC; Chiang KC; Feng TH; Chang KS; Chuang ST; Chen YJ; Tsui KH; Lee JC; Juang HH
    Mol Nutr Food Res; 2017 Sep; 61(9):. PubMed ID: 28181403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
    Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
    Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. As a Novel Tumor Suppressor, LHPP Promotes Apoptosis by Inhibiting the PI3K/AKT Signaling Pathway in Oral Squamous Cell Carcinoma.
    Liu S; Gao W; Lu Y; Zhou Q; Su R; Hasegawa T; Du J; Li M
    Int J Biol Sci; 2022; 18(2):491-506. PubMed ID: 35002505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma.
    Liu PY; Sheu JJ; Lin PC; Lin CT; Liu YJ; Ho LI; Chang LF; Wu WC; Chen SR; Chen J; Harn YC; Lin SZ; Tsai CH; Chiou TW; Harn HJ
    Invest New Drugs; 2012 Feb; 30(1):79-89. PubMed ID: 20809206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.
    Luo Q; Hu D; Hu S; Yan M; Sun Z; Chen F
    BMC Cancer; 2012 Nov; 12():517. PubMed ID: 23151022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro.
    Smolensky D; Rathore K; Bourn J; Cekanova M
    J Cell Biochem; 2017 Sep; 118(9):2615-2624. PubMed ID: 27649518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
    Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrin-α5 promoted the progression of oral squamous cell carcinoma and modulated PI3K/AKT signaling pathway.
    Fan QC; Tian H; Wang Y; Liu XB
    Arch Oral Biol; 2019 May; 101():85-91. PubMed ID: 30909080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxysophocarpine Retards the Growth and Metastasis of Oral Squamous Cell Carcinoma by Targeting the Nrf2/HO-1 Axis.
    Liu R; Peng J; Wang H; Li L; Wen X; Tan Y; Zhang L; Wan H; Chen F; Nie X
    Cell Physiol Biochem; 2018; 49(5):1717-1733. PubMed ID: 30231242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1.
    Jin S; Ma H; Yang W; Ju H; Wang L; Zhang Z
    J Mol Med (Berl); 2018 Jun; 96(6):513-525. PubMed ID: 29713760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells.
    Zainal NS; Gan CP; Lau BF; Yee PS; Tiong KH; Abdul Rahman ZA; Patel V; Cheong SC
    Phytomedicine; 2018 Jan; 39():33-41. PubMed ID: 29433681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression.
    Prgomet Z; Axelsson L; Lindberg P; Andersson T
    J Oral Pathol Med; 2015 Nov; 44(10):776-84. PubMed ID: 25459554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
    Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
    Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.